Prohost Biotech - Exclusive Biotech Research ~ A Comprehensive Resource for Biotech News

Halozyme and argenx Most Recent News

July 19, 2019 0

Halozyme and argenx Collaboration argenx (ARGX) dosed the first subject in phase 1 clinical trial for the safety, pharmacokinetics, and pharmacodynamics of its product efgartigimod plus Halozyme’s (HALO) drug delivery technology ENHANZE®. The drug aims at treating severe autoimmune diseases including myasthenia gravis (MG), immune thrombocytopenia (ITP)and skin blistering diseases. We find it good news that this first clinical trial …

The Gilead and Galapagos Agreement Is a Big Win for...

Regeneron’s Product Libtayo is Unique and Expected to Become a...

Gilead to File NDA for Rheumatoid Arthritis Drug Filgotinib. Karyopharm...

ImmunoGen: Experiencing Big Internal Changes

The FDA Approved AMAG Pharmaceuticals’ Product Vyleesi™ for Premenopausal Women...

Pfizer to Acquire Array Biopharma at $48 a Share

bluebird bio: Why This Firm’s Stock Gained $6.37 Yesterday

Novartis: Psoriatic Arthritis Patients on Cosentyx Had No Radiologic Progression...

bluebird bio Announces a European Conditional Approval of Its Gene...

Cara Therapeutics: More Positive Results from the Korsuva Product Trial...

Vertex: Good News and Good Decisions

Advaxis: Why This Small Firm’s Stock Outperformed on a Negative...

Will the Bear Escape Tonight from the Market? Regeneron and...

Bluebird bio and Celgene: Encouraging Clinical Trial Results for Last...

Exelixis and Aerie Have Good News

Gilead and insitro announce strategic collaboration to discover and develop...

Regeneron and Alnylam collaborative agreement will benefit these firms so...

Sangamo’s stock price Soars 52% in pre-market hours on hemophilia...

Aimmune Therapeutics’ product AR101 for the treatment of peanut allergy...

Today’s Highlights

Seattle Genetics Deserves Its Stock Rally

July 17, 2019 0

Seattle Genetics Stock Rallied Seattle Genetics (SGEN) financial results started with Clay Siegall, Ph.D., President and …

Takeda: Advancing the Potential for Off-the-Shelf, Highly Scalable and Lower Cost CAR T-Cell Therapy for Cancer Treatment.

July 17, 2019 0

CiRA, Takeda & T-CiRA Less than five years ago the Center for iPS Cell Research and Application …

Exelixis: Encouraging Results from Cabozantinib Trial and a Good Decision by the Firm

July 15, 2019 0

Exelixis is Expanding Cohorts for COSMIC-021, the Phase 1b Trial for Cabozantinib From Exelixis (EXEL) we …

Are Illumina’s 2019 Challenges Transitory?

July 12, 2019 2

Illumina Stock Dropped Following Their Preliminary Revenue Announcement Illumina (ILMN) stock dropped 16% following the firm's announcement …

Sangamo and Pfizer Announce Gene Therapy SB-525 Results in Hemophilia Patients and More

July 8, 2019 0

Sangamo and Pfizer Gene Therapy SB-525 Resulted in a Sustained Increase in Factor VIII Levels in …

Small Biotech Firms That Can Become Top-Tier Giants

July 2, 2019 0

Small Biotech Firms That Can Become Top-Tier Biotech Giants We Start With... Abeona Therapeutics Abeona Therapeutics …

Atossa Genetics Has Promising News

June 27, 2019 0

Atossa Genetics Promising News for Endoxifen Atossa Genetics (ATOS) has promising news from a Phase 2 trial …

Searching for a New Promising Development-Stage Biotech Firm We Found and Picked This One

June 25, 2019 0

Krystal Biotech Krystal Biotech (KRYS) is a gene therapy firm focused on developing topical intradermal therapeutics for rare …

News From Four Biotech Companies and Several Treatments

June 19, 2019 0

AstraZeneca and Merck PARP Inhibitor Lynparza The AstraZeneca (AZN) and Merck (MRK) PARP inhibitor Lynparza (olaparib) has …

Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

June 13, 2019 0

Nektar Announced Results for NKTR-358 During an oral session at the Annual European Congress of Rheumatology …

The Week in Review

The Week in Review #40

April 16, 2019 0

Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' (GILD) announcement at …

During the Departed Week

March 19, 2019 0

The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week …

Good news and setbacks during the departed week

March 5, 2019 0

The Week in Review #38 SYNOPSIS Good News and Setbacks During the Departed Week from the …

The Week in Review #37

February 19, 2019 0

From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation …

Now You See It, Now You Don’t

January 28, 2019 0

Now You See it, Now You Don’t Deliberate Omissions of Real Facts Real facts might be …

Politics and the Market

December 11, 2018 0

The Week in Review #35 Politics and the Market The market tumbled today as Theresa May, …

Improving on immunotherapy and preventing one of its serious side effects

November 13, 2018 0

The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. …

We call it the bad market

October 30, 2018 0

The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of …

Positive News

October 22, 2018 0

The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-stage …

Outperformance, underperformance and volatility

October 2, 2018 0

The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY …

Prohost Letters

Treating Hemoglobinopathies

June 21, 2019 0

Prohost Letter #433 Treating Hemoglobinopathies The most common genetic blood disorders are the hemoglobinopathies: sickle cell …

The ASCO 2019 Special Edition

June 11, 2019 0

Prohost Letter #432 The ASCO 2019 Special Edition SPRAYING FEAR The Victims Are The most disturbed …

Genomes, Genes and Gene Therapies

May 28, 2019 0

Prohost Letter #431 Genomes, Genes and Gene Therapies In this issue of the Prohost Letter we …

Prohost Letter #430

April 5, 2019 0

Prohost Letter #430 Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary …

End of the Year Decisions ~ Part 4

March 14, 2019 0

Prohost Letter #429 End of the Year Decisions ~ Part 4 We picked for our portfolio …

End of the Year Decisions ~ Part 3

February 10, 2019 0

Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this …

End of the Year Decisions Part 2

January 24, 2019 0

Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected …

End of the Year Decisions ~ Part 1

January 15, 2019 1

Prohost Letter #426 End of the Year Decisions ~ Part 1 We decided to make this …

The NEW Prohost Portfolio for 2019

January 3, 2019 0

The NEW Prohost Portfolio Small Important Changes We are making some very small but important changes …

When common sense fails to explain market performance

December 3, 2018 0

Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual …